Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ICOS Corporation -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (1021)	12/22/2003 10:53:36 AM
From: rkrw	Respond to of 1139

Taken from a yahoo post... Based on Lehman's report for the week ending 12/12/03, there were 14,157 new prescriptions. This represents 9.7 % of the new prescriptions for the week ending 12/12. Great numbers so far with no advertising, I will add. Impressive. After only the second full week.

To: Icebrg who wrote (1021)	1/7/2004 7:06:33 AM
From: Icebrg	Read Replies (1) \| Respond to of 1139

DNA-dependent protein kinase inhibitors as drug candidates for the treatment of cancer. 1: Mol Cancer Ther. 2003 Dec;2(12):1257-64. Links Kashishian A, Douangpanya H, Clark D, Schlachter ST, Eary CT, Schiro JG, Huang H, Burgess LE, Kesicki EA, Halbrook J. ICOS Corporation, Bothell, WA and Array Biopharma, Boulder, CO. Cancer presents a difficult challenge for oncologists, as there are few therapies that specifically target disease cells. Existing treatment strategies rely heavily on physical and chemical agents that nonspecifically affect DNA metabolism. To improve the effectiveness of these treatments, we have identified a new class of protein kinase inhibitor that targets a major DNA repair pathway. A representative of this class, 1-(2-hydroxy-4-morpholin-4-yl-phenyl)-ethanone, inhibits the DNA-dependent protein kinase (DNA-PK) and differs significantly from previously studied DNA-PK inhibitors both structurally and functionally. DNA-PK participates in the cellular response to and repair of chromosomal DNA double-strand breaks (DSBs). These new selective inhibitors recapitulate the phenotype of DNA-PK defective cell lines including those from SCID mice. These compounds directly inhibit the repair of DNA DSBs and consequently enhance the cytotoxicity of physical and chemical agents that induce DSBs but not other DNA lesions. In contrast to previously studied DNA-PK inhibitors, these compounds appear benign, exhibiting no toxic effects in the absence of DSB-inducing treatments. Most importantly, 1-(2-hydroxy-4-morpholin-4-yl-phenyl)-ethanone synergistically enhances radiation-induced tumor control in a mouse-human xenograft assay. These studies validate DNA-PK as a cancer drug target and suggest a new approach for enhancing the effects of existing cancer therapies. ncbi.nlm.nih.gov